Abstract
Tusa is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing tumors. The maximum tolerated dose (MTD) of tusa was defined as 100 mg/m2 every 2 weeks in the global study. This phase 1 dose escalation study (NCT03324113) aimed to evaluate safety of tusa in Japanese pts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
